Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016
Published May 31, 2016
504 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
- The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by id

  
Source:
Document ID
GMDHC8167IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents213
  List of Tables122
  List of Figures141
Introduction151
  Global Markets Direct Report Coverage151
Bile Duct Cancer (Cholangiocarcinoma) Overview161
Therapeutics Development172
  Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) Overview171
  Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) Comparative Analysis181
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Development by Companies194
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Investigation by Universities/Institutes231
Bile Duct Cancer (Cholangiocarcinoma) Pipeline Products Glance243
  Late Stage Products241
  Clinical Stage Products251
  Early Stage Products261
Bile Duct Cancer (Cholangiocarcinoma) Products under Development by Companies275
Bile Duct Cancer (Cholangiocarcinoma) Products under Investigation by Universities/Institutes321
Bile Duct Cancer (Cholangiocarcinoma) Companies Involved in Therapeutics Development3355
  4SC AG331
  Adgero Biopharmaceuticals, Inc.341
  Agios Pharmaceuticals, Inc.351
  Ariad Pharmaceuticals, Inc.361
  ArQule, Inc.371
  Array BioPharma Inc.381
  Arrien Pharmaceuticals, LLC391
  Aslan Pharmaceuticals Pte. Ltd.401
  Bavarian Nordic A/S411
  Bayer AG421
  Blueprint Medicines Corporation431
  Boehringer Ingelheim GmbH441
  Boston Biomedical, Inc.451
  Bristol-Myers Squibb Company461
  Celgene Corporation471
  CellAct Pharma GmbH481
  Cellceutix Corporation491
  Cellular Biomedicine Group, Inc.501
  Concordia Healthcare Corp.511
  Cornerstone Pharmaceuticals, Inc.521
  Delcath Systems, Inc.531
  Eisai Co., Ltd.541
  Eli Lilly and Company551
  Exelixis, Inc.561
  F. Hoffmann-La Roche Ltd.571
  Halozyme Therapeutics, Inc.581
  Innopharmax Inc.591
  Johnson &Johnson601
  Komipharm International Co., Ltd.611
  Loxo Oncology, Inc.621
  Mebiopharm Co., Ltd.631
  MedImmune, LLC641
  Merck &Co., Inc.651
  Merrimack Pharmaceuticals, Inc.661
  NanoCarrier Co., Ltd.671
  NormOxys, Inc.681
  Novartis AG691
  NuCana BioMed Limited701
  OncoTherapy Science, Inc.711
  Ono Pharmaceutical Co., Ltd.721
  Panacea Pharmaceuticals, Inc.731
  PCI Biotech Holding ASA741
  Pfizer Inc.751
  Plexxikon Inc.761
  Provecs Medical GmbH771
  Puma Biotechnology, Inc.781
  RedHill Biopharma Ltd.791
  Sanofi801
  Senhwa Biosciences, Inc.811
  Spectrum Pharmaceuticals, Inc.821
  Sun Pharma Advanced Research Company Ltd.831
  Taiwan Liposome Company, Ltd.841
  tella Inc851
  Threshold Pharmaceuticals, Inc.861
  VasGene Therapeutics, Inc.871
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Assessment8814
  Assessment by Monotherapy Products881
  Assessment by Combination Products891
  Assessment by Target904
  Assessment by Mechanism of Action944
  Assessment by Route of Administration982
  Assessment by Molecule Type1002
Drug Profiles102195
  ABC-294640 - Drug Profile1021
    Product Description1021
    Mechanism of Action1021
    R&D Progress1023
  afatinib dimaleate - Drug Profile1051
    Product Description1051
    Mechanism of Action1051
    R&D Progress1055
  AG-120 - Drug Profile1101
    Product Description1101
    Mechanism of Action1101
    R&D Progress1102
  amcasertib - Drug Profile1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1122
  ARN-5032 - Drug Profile1141
    Product Description1141
    Mechanism of Action1141
    R&D Progress1141
  ARQ-087 - Drug Profile1151
    Product Description1151
    Mechanism of Action1151
    R&D Progress1151
  binimetinib - Drug Profile1161
    Product Description1161
    Mechanism of Action1161
    R&D Progress1165
  BLU-554 - Drug Profile1211
    Product Description1211
    Mechanism of Action1211
    R&D Progress1211
  bromopyruvate - Drug Profile1221
    Product Description1221
    Mechanism of Action1221
    R&D Progress1221
  cabozantinib s-malate - Drug Profile1231
    Product Description1231
    Mechanism of Action1231
    R&D Progress1235
  CAP-7.1 - Drug Profile1281
    Product Description1281
    Mechanism of Action1281
    R&D Progress1282
  Cellular Immunotherapy for Biliary Cancer and Pancreatic Cancer - Drug Profile1301
    Product Description1301
    Mechanism of Action1301
    R&D Progress1301
  Cellular Immunotherapy to Target HER1 for Oncology - Drug Profile1311
    Product Description1311
    Mechanism of Action1311
    R&D Progress1311
  ceritinib - Drug Profile1321
    Product Description1321
    Mechanism of Action1321
    R&D Progress1323
  CGX-1321 - Drug Profile1351
    Product Description1351
    Mechanism of Action1351
    R&D Progress1351
  cisplatin - Drug Profile1361
    Product Description1361
    Mechanism of Action1361
    R&D Progress1362
  CPI-613 - Drug Profile1381
    Product Description1381
    Mechanism of Action1381
    R&D Progress1383
  crizotinib - Drug Profile1411
    Product Description1411
    Mechanism of Action1411
    R&D Progress1414
  dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile1451
    Product Description1451
    Mechanism of Action1451
    R&D Progress1452
  dasatinib - Drug Profile1471
    Product Description1471
    Mechanism of Action1471
    R&D Progress1473
  DKN-01 - Drug Profile1501
    Product Description1501
    Mechanism of Action1501
    R&D Progress1502
  durvalumab - Drug Profile1521
    Product Description1521
    Mechanism of Action1521
    R&D Progress1525
  enasidenib - Drug Profile1571
    Product Description1571
    Mechanism of Action1571
    R&D Progress1573
  erdafitinib - Drug Profile1601
    Product Description1601
    Mechanism of Action1601
    R&D Progress1602
  evofosfamide - Drug Profile1621
    Product Description1621
    Mechanism of Action1621
    R&D Progress1628
  gemcitabine hydrochloride - Drug Profile1701
    Product Description1701
    Mechanism of Action1701
    R&D Progress1701
  gemcitabine hydrochloride - Drug Profile1711
    Product Description1711
    Mechanism of Action1711
    R&D Progress1712
  HTI-1511 - Drug Profile1731
    Product Description1731
    Mechanism of Action1731
    R&D Progress1731
  Im-01 - Drug Profile1741
    Product Description1741
    Mechanism of Action1741
    R&D Progress1741
  IMB-101 - Drug Profile1751
    Product Description1751
    Mechanism of Action1751
    R&D Progress1751
  IMB-102 - Drug Profile1761
    Product Description1761
    Mechanism of Action1761
    R&D Progress1761
  infigratinib - Drug Profile1771
    Product Description1771
    Mechanism of Action1771
    R&D Progress1772
  KM-3174 - Drug Profile1791
    Product Description1791
    Mechanism of Action1791
    R&D Progress1794
  KML-001 - Drug Profile1831
    Product Description1831
    Mechanism of Action1831
    R&D Progress1832
  lenvatinib mesylate - Drug Profile1851
    Product Description1851
    Mechanism of Action1851
    R&D Progress1856
  LOXO-101 - Drug Profile1911
    Product Description1911
    Mechanism of Action1911
    R&D Progress1912
  LY-3039478 - Drug Profile1931
    Product Description1931
    Mechanism of Action1931
    R&D Progress1931
  MBPY-005 - Drug Profile1941
    Product Description1941
    Mechanism of Action1941
    R&D Progress1941
  melphalan - Drug Profile1951
    Product Description1951
    Mechanism of Action1951
    R&D Progress1953
  merestinib - Drug Profile1981
    Product Description1981
    Mechanism of Action1981
    R&D Progress1981
  metenkefalin - Drug Profile1991
    Product Description1991
    Mechanism of Action1991
    R&D Progress1991
  MK-2206 - Drug Profile2001
    Product Description2001
    Mechanism of Action2001
    R&D Progress2003
  napabucasin - Drug Profile2031

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bile-Duct-Cancer-Cholangiocarcinoma-Pipeline-Review-H1-2016-2088-15910>
  
APA:
Global Markets Direct - Market Research. (2016). Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bile-Duct-Cancer-Cholangiocarcinoma-Pipeline-Review-H1-2016-2088-15910>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.